VNDA Quote, Financials, Valuation and Earnings

Amicus Therapeutics has a net margin of -9.24% compared to Vanda Pharmaceuticals's net margin of 9.85%. Vanda Pharmaceuticals's return on equity of -3.49% beat Amicus Therapeutics's return on equity of -35.23%.

Vanda Pharmaceuticals has a consensus price target of $12.67, signalling upside risk potential of 198.04%. On the other hand Amicus Therapeutics has an analysts' consensus of $16.64 which suggests that it could grow by 126.35%. Given that Vanda Pharmaceuticals has higher upside potential than Amicus Therapeutics, analysts believe Vanda Pharmaceuticals is more attractive than Amicus Therapeutics.

Vanda Pharmaceuticals has a beta of 0.720, which suggesting that the stock is 28.044% less volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.795, suggesting its less volatile than the S&P 500 by 20.519%.

Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

Vanda Pharmaceuticals quarterly revenues are $53.2M, which are smaller than Amicus Therapeutics quarterly revenues of $149.7M. Vanda Pharmaceuticals's net income of -$4.9M is lower than Amicus Therapeutics's net income of $14.7M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.24x versus 4.23x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

MediciNova has a net margin of -9.24% compared to Vanda Pharmaceuticals's net margin of --. Vanda Pharmaceuticals's return on equity of -3.49% beat MediciNova's return on equity of --.

Vanda Pharmaceuticals has a consensus price target of $12.67, signalling upside risk potential of 198.04%. On the other hand MediciNova has an analysts' consensus of $8.33 which suggests that it could grow by 434.19%. Given that MediciNova has higher upside potential than Vanda Pharmaceuticals, analysts believe MediciNova is more attractive than Vanda Pharmaceuticals.

Vanda Pharmaceuticals has a beta of 0.720, which suggesting that the stock is 28.044% less volatile than S&P 500. In comparison MediciNova has a beta of 0.750, suggesting its less volatile than the S&P 500 by 24.968%.

Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MediciNova offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. MediciNova pays out -- of its earnings as a dividend.

Vanda Pharmaceuticals quarterly revenues are $53.2M, which are larger than MediciNova quarterly revenues of --. Vanda Pharmaceuticals's net income of -$4.9M is lower than MediciNova's net income of -$2.8M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while MediciNova's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.24x versus -- for MediciNova. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical has a net margin of -9.24% compared to Vanda Pharmaceuticals's net margin of -80.9%. Vanda Pharmaceuticals's return on equity of -3.49% beat Ultragenyx Pharmaceutical's return on equity of -194.36%.

Vanda Pharmaceuticals has a consensus price target of $12.67, signalling upside risk potential of 198.04%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $91.80 which suggests that it could grow by 141.01%. Given that Vanda Pharmaceuticals has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Vanda Pharmaceuticals is more attractive than Ultragenyx Pharmaceutical.

Vanda Pharmaceuticals has a beta of 0.720, which suggesting that the stock is 28.044% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.607, suggesting its less volatile than the S&P 500 by 39.255%.

Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

Vanda Pharmaceuticals quarterly revenues are $53.2M, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $164.9M. Vanda Pharmaceuticals's net income of -$4.9M is higher than Ultragenyx Pharmaceutical's net income of -$133.4M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.24x versus 6.15x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Vistagen Therapeutics has a net margin of -9.24% compared to Vanda Pharmaceuticals's net margin of -6020.94%. Vanda Pharmaceuticals's return on equity of -3.49% beat Vistagen Therapeutics's return on equity of -45.8%.

Vanda Pharmaceuticals has a consensus price target of $12.67, signalling upside risk potential of 198.04%. On the other hand Vistagen Therapeutics has an analysts' consensus of $13.00 which suggests that it could grow by 485.59%. Given that Vistagen Therapeutics has higher upside potential than Vanda Pharmaceuticals, analysts believe Vistagen Therapeutics is more attractive than Vanda Pharmaceuticals.

Vanda Pharmaceuticals has a beta of 0.720, which suggesting that the stock is 28.044% less volatile than S&P 500. In comparison Vistagen Therapeutics has a beta of 0.562, suggesting its less volatile than the S&P 500 by 43.775%.

Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vistagen Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. Vistagen Therapeutics pays out -- of its earnings as a dividend.

Vanda Pharmaceuticals quarterly revenues are $53.2M, which are larger than Vistagen Therapeutics quarterly revenues of $234K. Vanda Pharmaceuticals's net income of -$4.9M is higher than Vistagen Therapeutics's net income of -$14.1M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while Vistagen Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.24x versus 94.60x for Vistagen Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.